Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGenus Regulatory News (GNS)

Share Price Information for Genus (GNS)

Share Price is delayed by 15 minutes
Get Live Data
2,020.00    -52.00 (-2.51%)
Bid:
2,008.00
Ask:
2,016.00
Spread: 8.00 (0.398%)
Market Cap: £1.34b
GNS Live PriceLast checked at - London Stock Exchange

Intraday Genus Share Chart

Director/PDMR Shareholding

20 Sep 2011 15:07

RNS Number : 5938O
Genus PLC
20 September 2011
 

20 September 2011

 

Genus plc

 

('Genus' or 'the Company')

 

Director/PDMR Shareholding

 

 

Genus announces that of 117,359 ordinary shares of 10 pence each in the Company ("Ordinary Shares") which vested today in favour of Richard Wood, Chief Executive, under the Genus 2004 Performance Share Plan (the "Plan"), 117,359 Ordinary Shares were today sold on behalf of Richard Wood at a price of 1,000 pence per Ordinary Share.

 

Richard Wood's direct shareholding in the Company stands at 45,856 Ordinary Shares which represents 0.08% of the issued share capital of the Company which is currently 60,239,150 Ordinary Shares.

 

Genus also announces that of 46,927 Ordinary Shares that vested today in favour of Ian Biggs, Head of Global Product & Business Strategy, under the Plan, 46,927 Ordinary Shares were today sold on behalf of Ian Biggs at a price of 1,000 pence per Ordinary Share.

 

Ian Biggs' direct shareholding in the Company stands at 3,375 Ordinary Shares which represents 0.01% of the issued share capital of the Company. In addition, he remains the beneficial owner of 78,415 conditional nil-cost options under the Plan.

 

Of 41,061 Ordinary Shares that vested today in favour of Thomas Philip Acton, Chief Operating Officer of Europe & The Far East, under the Plan, 31,061 Ordinary Shares were today sold on behalf of Thomas Philip Acton at a price of 1,000 pence per Ordinary Share.

 

Thomas Philip Acton's direct shareholding in the Company now stands at 31,104 Ordinary Shares which represents 0.06% of the issued share capital of the Company. In addition, he remains the beneficial owner of 78,415 conditional nil-cost options under the Plan.

 

Of 28,156 Ordinary Shares that vested today in favour of Ian Farrelly, Group Company Secretary & General Counsel, under the Plan, 28,156 Ordinary Shares were today sold on behalf of Ian Farrelly at a price of 1,000 pence per Ordinary Share.

 

Ian Farrelly has no direct shareholding in the Company. He remains the beneficial owner of 61,462 conditional nil-cost options under the Plan.

 

Genus further announces that of 1,619 Ordinary Shares which vested today in favour of Bill Christianson, Chief Operating Officer, The Americas, under the Genus 2004 Executive Share Option Plan (the "ESOP"), 1,619 Ordinary Shares were today sold on behalf of Bill Christianson at a price of 1,000 pence per Ordinary Share.

 

Bill Christianson has no direct shareholding in the Company and is the beneficial owner of 56,953 conditional nil-cost options and 18,970 market value share options.

 

Of 6,673 Ordinary Shares which vested today in favour of David Crosby, Group Financial Controller, under the ESOP, 6,673 Ordinary Shares were today sold on behalf of David Crosby at a price of 1,000 pence per Ordinary Share.

 

David Crosby has no direct shareholding in the Company and is the beneficial owner of 53,843 conditional nil-cost options.

 

 

For further information please contact:

 

Cara Crichton

Assistant Company Secretary

Genus plc

 

Tel: 01256 345996

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSURRSRANAKUAR
Date   Source Headline
10th Oct 20134:35 pmRNSAnnual Report & Annual General Meeting
3rd Oct 20132:00 pmRNSAdditional Listing
2nd Oct 20135:00 pmRNSTotal Voting Rights
27th Sep 20136:19 pmRNSDirector/PDMR Shareholding
23rd Sep 20137:00 amRNSGenus to Acquire Génétiporc
3rd Sep 20133:04 pmRNSCorrection of Record Date
3rd Sep 20137:00 amRNSPreliminary Results
31st Jul 20133:00 pmRNSBlocklisting Interim Review
25th Jul 201310:14 amRNSCompany Secretary Appointment
18th Jul 20139:00 amRNSHolding(s) in Company
11th Jun 20135:07 pmRNSHolding(s) in Company
4th Jun 20139:10 amRNSHolding(s) in Company
31st May 20132:00 pmRNSTotal Voting Rights
23rd May 20138:22 amRNSDirector/PDMR Shareholding
21st May 20134:56 pmRNSHolding(s) in Company
30th Apr 20137:00 amRNSInterim Management Statement
8th Apr 20136:09 pmRNSHolding(s) in Company
8th Apr 201310:27 amRNSHolding(s) in Company
28th Mar 20134:13 pmRNSHolding(s) in Company
28th Mar 20133:51 pmRNSTotal Voting Rights
21st Mar 20132:00 pmRNSHolding(s) in Company
11th Mar 20134:07 pmRNSDirector/PDMR Shareholding
4th Mar 20132:00 pmRNSHolding(s) in Company
28th Feb 20132:30 pmRNSTotal Voting Rights
28th Feb 20132:00 pmRNSDirector/PDMR Shareholding
25th Feb 20134:21 pmRNSDirector/PDMR Shareholding
25th Feb 20137:00 amRNSInterim Results
25th Feb 20137:00 amRNSSecond New Joint Venture in China
4th Feb 201310:00 amRNSHolding(s) in Company
31st Jan 20132:00 pmRNSBlocklisting Interim Review
31st Jan 20132:00 pmRNSTotal Voting Rights
8th Jan 20132:00 pmRNSHolding(s) in Company
13th Dec 20127:00 amRNSDirectorate Change
7th Dec 201210:00 amRNSDirector/PDMR Shareholding
30th Nov 20122:00 pmRNSTotal Voting Rights
14th Nov 201210:00 amRNSHolding(s) in Company
8th Nov 20123:30 pmRNSAGM Statement
8th Nov 20127:00 amRNSAGM and Interim Management Statement
31st Oct 20122:03 pmRNSTotal Voting Rights
26th Oct 201210:00 amRNSHolding(s) in Company
17th Oct 201210:00 amRNSHolding(s) in Company
9th Oct 20122:00 pmRNSAnnual Report and details of AGM
28th Sep 20122:00 pmRNSTotal Voting Rights
27th Sep 201211:00 amRNSAdditional Listing
27th Sep 20128:00 amRNSHolding(s) in Company
26th Sep 20124:01 pmRNSDirector/PDMR Shareholding
4th Sep 20127:00 amRNSPreliminary Results
31st Aug 20122:00 pmRNSTotal Voting Rights
23rd Aug 20126:18 pmRNSHolding(s) in Company
20th Aug 20127:00 amRNSAppointment of Joint Broker

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.